FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3204392012> ?p ?o ?g. }

• W3204392012 abstract "The aminoisoquinoline FX-9 shows pro-apoptotic and antimitotic effects against lymphoblastic leukemia cells and prostate adenocarcinoma cells. In contrast, decreased cytotoxic effects against non-neoplastic blood cells, chondrocytes, and fibroblasts were observed. However, the actual FX-9 molecular mode of action is currently not fully understood.In this study, microarray gene expression analysis comparing FX-9 exposed and unexposed prostate cancer cells (PC-3 representing castration-resistant prostate cancer), followed by pathway analysis and gene annotation to functional processes were performed. Immunocytochemistry staining was performed with selected targets.Expression analysis revealed 0.83% of 21,448 differential expressed genes (DEGs) after 6-h exposure of FX-9 and 0.68% DEGs after 12-h exposure thereof. Functional annotation showed that FX-9 primarily caused an activation of inflammatory response by non-canonical nuclear factor-kappa B (NF-κB) signaling. The 6-h samples showed activation of the cell cycle inhibitor CDKN1A which might be involved in the secondary response in 12-h samples. This secondary response predominantly consisted of cell cycle-related changes, with further activation of CDKN1A and inhibition of the transcription factor E2F1, including downstream target genes, resulting in G1-phase arrest. Matching our previous observations on cellular level senescence signaling pathways were also found enriched. To verify these results immunocytochemical staining of p21 Waf1/Cip1 (CDKN1A), E2F1 (E2F1), PAI-1 (SERPNE1), and NFkB2/NFkB p 100 (NFKB2) was performed. Increased expression of p21 Waf1/Cip1 and NFkB2/NFkB p 100 after 24-h exposure to FX-9 was shown. E2F1 and PAI-1 showed no increased expression.FX-9 induced G1-phase arrest of PC-3 cells through activation of the cell cycle inhibitor CDKN1A, which was initiated by an inflammatory response of noncanonical NF-κB signaling." @default.
• W3204392012 created "2021-10-11" @default.
• W3204392012 creator A5005182277 @default.
• W3204392012 creator A5006621343 @default.
• W3204392012 creator A5045380937 @default.
• W3204392012 creator A5060233539 @default.
• W3204392012 creator A5071303964 @default.
• W3204392012 creator A5075822984 @default.
• W3204392012 creator A5079524945 @default.
• W3204392012 creator A5080777876 @default.
• W3204392012 creator A5087351196 @default.
• W3204392012 date "2021-10-08" @default.
• W3204392012 modified "2023-09-26" @default.
• W3204392012 title "Novel chemotherapeutic agent FX-9 activates NF-κB signaling and induces G1 phase arrest by activating CDKN1A in a human prostate cancer cell line" @default.
• W3204392012 cites W1521275673 @default.
• W3204392012 cites W1904433804 @default.
• W3204392012 cites W1970924670 @default.
• W3204392012 cites W1978567987 @default.
• W3204392012 cites W1978888457 @default.
• W3204392012 cites W1984252723 @default.
• W3204392012 cites W1987175913 @default.
• W3204392012 cites W1990532502 @default.
• W3204392012 cites W1996121530 @default.
• W3204392012 cites W2004042953 @default.
• W3204392012 cites W2007618242 @default.
• W3204392012 cites W2013103023 @default.
• W3204392012 cites W2015519364 @default.
• W3204392012 cites W2016309093 @default.
• W3204392012 cites W2023877008 @default.
• W3204392012 cites W2036981062 @default.
• W3204392012 cites W2040807564 @default.
• W3204392012 cites W2047280231 @default.
• W3204392012 cites W2048008261 @default.
• W3204392012 cites W2055047482 @default.
• W3204392012 cites W2075069597 @default.
• W3204392012 cites W2075760937 @default.
• W3204392012 cites W2077575210 @default.
• W3204392012 cites W2084680530 @default.
• W3204392012 cites W2085896082 @default.
• W3204392012 cites W2088887503 @default.
• W3204392012 cites W2089100941 @default.
• W3204392012 cites W2093814864 @default.
• W3204392012 cites W2094863064 @default.
• W3204392012 cites W2117969095 @default.
• W3204392012 cites W2119874496 @default.
• W3204392012 cites W2150782426 @default.
• W3204392012 cites W2152812885 @default.
• W3204392012 cites W2163974192 @default.
• W3204392012 cites W2166374178 @default.
• W3204392012 cites W2283979782 @default.
• W3204392012 cites W2343423203 @default.
• W3204392012 cites W2414096785 @default.
• W3204392012 cites W2470223656 @default.
• W3204392012 cites W2600455045 @default.
• W3204392012 cites W2620769476 @default.
• W3204392012 cites W2621171915 @default.
• W3204392012 cites W2732055076 @default.
• W3204392012 cites W2753171732 @default.
• W3204392012 cites W2901503059 @default.
• W3204392012 cites W2936645220 @default.
• W3204392012 cites W2969845879 @default.
• W3204392012 cites W2985945616 @default.
• W3204392012 cites W3083787933 @default.
• W3204392012 cites W4231254854 @default.
• W3204392012 cites W4242700871 @default.
• W3204392012 cites W2193839702 @default.
• W3204392012 doi "https://doi.org/10.1186/s12885-021-08836-y" @default.
• W3204392012 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8501574" @default.
• W3204392012 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34625047" @default.
• W3204392012 hasPublicationYear "2021" @default.
• W3204392012 type Work @default.
• W3204392012 sameAs 3204392012 @default.
• W3204392012 citedByCount "0" @default.
• W3204392012 crossrefType "journal-article" @default.
• W3204392012 hasAuthorship W3204392012A5005182277 @default.
• W3204392012 hasAuthorship W3204392012A5006621343 @default.
• W3204392012 hasAuthorship W3204392012A5045380937 @default.
• W3204392012 hasAuthorship W3204392012A5060233539 @default.
• W3204392012 hasAuthorship W3204392012A5071303964 @default.
• W3204392012 hasAuthorship W3204392012A5075822984 @default.
• W3204392012 hasAuthorship W3204392012A5079524945 @default.
• W3204392012 hasAuthorship W3204392012A5080777876 @default.
• W3204392012 hasAuthorship W3204392012A5087351196 @default.
• W3204392012 hasBestOaLocation W32043920121 @default.
• W3204392012 hasConcept C121608353 @default.
• W3204392012 hasConcept C126322002 @default.
• W3204392012 hasConcept C153911025 @default.
• W3204392012 hasConcept C2780192828 @default.
• W3204392012 hasConcept C29537977 @default.
• W3204392012 hasConcept C502942594 @default.
• W3204392012 hasConcept C71924100 @default.
• W3204392012 hasConcept C86803240 @default.
• W3204392012 hasConcept C96232424 @default.
• W3204392012 hasConceptScore W3204392012C121608353 @default.
• W3204392012 hasConceptScore W3204392012C126322002 @default.
• W3204392012 hasConceptScore W3204392012C153911025 @default.
• W3204392012 hasConceptScore W3204392012C2780192828 @default.
• W3204392012 hasConceptScore W3204392012C29537977 @default.
• W3204392012 hasConceptScore W3204392012C502942594 @default.
• W3204392012 hasConceptScore W3204392012C71924100 @default.

• next